What’s Next in Oncology: Research Breakthroughs from the 2025 ASCO® Annual Meeting

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen.  She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others.  She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007.

Dr. Nataliya Uboha is a faculty member in the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine and a member of Carbone Cancer Center (UWCCC). She is a Faculty Leader for the Early Phase Oncology Therapeutics Program at UWCCC. As a medical oncologist, she specializes in treating patients with GI malignancies and focuses on gastroesophageal cancers. She has extensive clinical research experience, particularly emphasizing phase 1 and biomarker-based clinical studies. Dr. Uboha has several regional and national leadership roles. She is a Chair of the ECOG-ACRIN Upper GI working group and a Co-Chair of the National Cancer Institute Upper GI Taskforce. Dr. Uboha is a member of the NCCN Guidelines Committee for esophageal and gastric cancers. Dr. Uboha also has several roles with the American Society of Clinical Oncology (ASCO), serving as a scientific committee track chair for the 2025 ASCO Annual Meeting and as a member of the ASCO guidelines committee for upper GI cancers.

Dr. Cynthia Ma is Professor of Medicine within the Division of Oncology, Department of Medicine, at Washington University School of Medicine, in St. Louis, MO. She is a breast oncologist and a physician scientist, whose research focuses on endocrine therapy and targeted agents for the treatment of breast cancer. She has led several biomarker directed, investigator initiated trials including neoadjuvant studies of endocrine agents in combination with inhibitors against PI3K pathway or the CDK4/6 in patients with locally advanced estrogen receptor positive breast cancer. She is the study chair for the ongoing ALLIANCE ALTERNATE trial, which evaluates Ki67 based biomarkers as well as genomic predictors of endocrine responsiveness and a member of the Alliance Breast Committee. Dr. Ma is the clinical director of the Breast Cancer Program in Medical Oncology at Washington University School of Medicine; Co-leader of the Breast Cancer Focus Group and Breast Cancer Research Program at Siteman Cancer Center located in St. Louis, MO. She is a member of multiple scientific and research committees; Section Editor for Current Breast Cancer Report and serves as an Editorial Board Member on several major journals. Dr. Ma was recently elected as the Vice President of CAHON (Chinese American Hematologist and Oncologist Network).

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.